Role of interleukin-6 in stress, sleep, and fatigue

Annals of the New York Academy of Sciences

Volumn 1261, Issue 1, 2012, Pages 88-96

  Rohleder, Nicolas ^a   Aringer, Martin ^b   Boentert, Matthias ^c  

^a BRANDEIS UNIVERSITY   (United States)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Fatigue; Interleukin 6; Rheumatoid arthritis; Sleep; Stress

Indexed keywords

ETANERCEPT; FERROPORTIN; HEPCIDIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; NORADRENALIN; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA;

ADRENALECTOMY; ADVERSE OUTCOME; ANEMIA; ANGER; ANXIETY; CIRCADIAN RHYTHM; CROSS-SECTIONAL STUDY; DAYTIME SOMNOLENCE; DISEASE ACTIVITY; DNA BINDING; FATIGUE; HUMAN; HYPERCORTISOLISM; HYPERSOMNIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSOMNIA; LOWEST INCOME GROUP; MEDITATION; MENTAL STRESS; META ANALYSIS (TOPIC); NARCOLEPSY; NONHUMAN; PARASOMNIA; PHYSIOLOGICAL STRESS; RHEUMATOID ARTHRITIS; SHORT SURVEY; SLEEP; SLEEP APNEA SYNDROME; SLEEP DISORDER; SLEEP QUALITY; SLEEP TIME; SLEEP WAKING CYCLE; STRESS; TREADMILL EXERCISE; YOGA;

EID: 84864106582     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06634.x     Document Type: Short Survey

References (104)

1. Benveniste, E.N. 1992. Inflammatory cytokines within the central nervous system: sources, function, and mechanism of action. Am. J. Physiol. 263: C1-C16.
2. Cannon, J.G. 2000. Inflammatory cytokines in nonpathological states. News Physiol. Sci. 15: 298-303.
3. Besedovsky, H.O. & A. del Rey. 1996. Immune-neuro-endocrine interactions: facts and hypotheses. Endocr. Rev. 17: 64-102.
4. Sternberg, E.M. 2001. Neuroendocrine regulation of autoimmune/inflammatory disease. J. Endocrinol. 169: 429-435.
5. Nishimoto, N. & T. Kishimoto. 2006. Interleukin 6: from bench to bedside. Nat. Clin. Pract. Rheumatol. 2: 619-626.
6. Yamasaki, K. et al. 1988. Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science 241: 825-828.
7. Taga, T. et al. 1989. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58: 573-581.
8. Yin, T. et al. 1993. Involvement of IL-6 signal transducer gp130 in IL-11-mediated signal transduction. J. Immunol. 151: 2555-2561.
9. Zhong, Z., Z. Wen & J.E.J. Darnell. 1994. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264: 95-98.
10. Narazaki, M. et al. 1994. Activation of JAK2 kinase mediated by the interleukin 6 signal transducer gp130. Proc. Natl. Acad. Sci. U.S.A. 91: 2285-2289.
11. Naka, T., N. Nishimoto & T. Kishimoto. 2002. The paradigm of IL-6: from basic science to medicine. Arthritis Res. 4 Suppl 3: S233-S242.
12. Rose-John, S. et al. 2006. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J. Leukoc. Biol. 80: 227-236.
13. Papanicolaou, D.A. & A.N. Vgontzas. 2000. Interleukin-6: the endocrine cytokine. J. Clin. Endocrinol. Metab. 85: 1331-1333.
14. Mohamed-Ali, V. et al. 2001. beta-Adrenergic regulation of IL-6 release from adipose tissue: in vivo and in vitro studies. J. Clin. Endocrinol. Metab. 86: 5864-5869.
15. Sironi, M. et al. 1989. IL-1 stimulates IL-6 production in endothelial cells. J. Immunol. 142: 549-553.
16. Ershler, W.B. 1993. Interleukin-6: a cytokine for gerontologists. J. Am. Geriatr. Soc. 41: 176-181.
17. Ershler, W.B., W.H. Sun & N. Binkley. 1994. The role of interleukin-6 in certain age-related diseases. Drugs Aging 5: 358-365.
18. Bruunsgaard, H. et al. 2003. Predicting death from tumour necrosis factor-alpha and interleukin-6 in 80-year-old people. Clin. Exp. Immunol. 132: 24-31.
19. Baumann, H. & J. Gauldie. 1994. The acute phase response. Immunol. Today 15: 74-80.
20. Olivadoti, M.D. & M.R. Opp. 2008. Effects of i.c.v. administration of interleukin-1 on sleep and body temperature of interleukin-6-deficient mice. Neuroscience 153: 338-348.
21. Garlanda, C. et al. 2005. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu. Rev. Immunol. 23: 337-366.
22. Xing, Z. et al. 1998. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J. Clin. Invest. 101: 311-320.
23. Gabay, C. & I. Kushner. 1999. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 340: 448-454.
24. Aletaha, D. et al. 2010. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann. Rheum. Dis. 69: 1580-1588.
25. Radovits, B.J. et al. 2010. Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis. Arthritis Care Res. 62: 362-370.
26. Felson, D.T. et al. 2011. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 63: 573-586.
27. Szalai, A.J. et al. 1998. Testosterone and IL-6 requirements for human C-reactive protein gene expression in transgenic mice. J. Immunol. 160: 5294-5299.
28. Genovese, M.C. et al. 2008. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 58: 2968-2980.
29. Nishimoto, N. et al. 2007. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann. Rheum. Dis. 66: 1162-1167.
30. Smolen, J.S. et al. 2008. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371: 987-997.
31. Kremer, J.M. et al. 2011. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 63: 609-621.
32. Burmester, G.R. et al. 2011. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann. Rheum. Dis. 70: 755-759.
33. Iking-Konert, C. et al. 2011. Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria. Ann. Rheum. Dis. 70: 1986-1990.
34. Han, C. et al. 2007. Association of anemia and physical disability among patients with rheumatoid arthritis. J. Rheumatol. 34: 2177-2182.
35. Nikolaisen, C., Y. Figenschau & J.C. Nossent. 2008. Anemia in early rheumatoid arthritis is associated with interleukin 6-mediated bone marrow suppression, but has no effect on disease course or mortality. J. Rheumatol. 35: 380-386.
36. Emery, P. et al. 2008. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis. 67: 1516-1523.
37. Nemeth, E. et al. 2004. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306: 2090-2093.
38. Nemeth, E. et al. 2004. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 113: 1271-1276.
39. Hess, A. et al. 2011. Blockade of TNF-alpha rapidly inhibits pain responses in the central nervous system. Proc. Natl. Acad. Sci. U.S.A. 108: 3731-3736.
40. Hewlett, S. et al. 2011. Fatigue in rheumatoid arthritis: time for a conceptual model. Rheumatology 50: 1004-1006.
41. Borbely, A.A. 1982. A two process model of sleep regulation. Hum. Neurobiol. 1: 195-204.
42. Morris, C.J., D. Aeschbach & F.A. Scheer. 2012. Circadian system, sleep and endocrinology. Mol. Cell Endocrinol. 349: 91-104.
43. Neu, D. et al. 2010. Do 'sleepy' and 'tired' go together? Rasch analysis of the relationships between sleepiness, fatigue and nonrestorative sleep complaints in a nonclinical population sample. Neuroepidemiology 35: 1-11.
44. Gangwisch, J.E. et al. 2006. Short sleep duration as a risk factor for hypertension: analyses of the first National Health and Nutrition Examination Survey. Hypertension 47: 833-839.
45. Gangwisch, J.E. et al. 2007. Sleep duration as a risk factor for diabetes incidence in a large U.S. sample. Sleep 30: 1667-1673.
46. Grandner, M.A. et al. 2010. Mortality associated with short sleep duration: the evidence, the possible mechanisms, and the future. Sleep Med. Rev. 14: 191-203.
47. Patel, S.R. et al. 2004. A prospective study of sleep duration and mortality risk in women. Sleep 27: 440-444.
48. Ancoli-Israel, S. 2006. The impact and prevalence of chronic insomnia and other sleep disturbances associated with chronic illness. Am. J. Manag. Care 12: S221-S229.
49. Irwin, M. 2002. Effects of sleep and sleep loss on immunity and cytokines. Brain Behav. Immun. 16: 503-512.
50. Okun, M.L., M. Coussons-Read & M. Hall. 2009. Disturbed sleep is associated with increased C-reactive protein in young women. Brain Behav. Immun. 23: 351-354.
51. Patel, S.R. et al. 2009. Sleep duration and biomarkers of inflammation. Sleep 32: 200-204.
52. Vgontzas, A.N. et al. 1997. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J. Clin. Endocrinol. Metab. 82: 1313-1316.
53. Vgontzas, A.N. et al. 1999. Circadian interleukin-6 secretion and quantity and depth of sleep. J. Clin. Endocrinol. Metab. 84: 2603-2607.
54. Vgontzas, A.N. et al. 2005. IL-6 and its circadian secretion in humans. Neuroimmunomodulation 12: 131-140.
55. Redwine, L. et al. 2000. Effects of sleep and sleep deprivation on interleukin-6, growth hormone, cortisol, and melatonin levels in humans. J. Clin. Endocrinol. Metab. 85: 3597-3603.
56. Dimitrov, S. et al. 2006. Sleep enhances IL-6 trans-signaling in humans. FASEB J. 20: 2174-2176.
57. Motzkus, D., U. Albrecht & E. Maronde. 2002. The human PER1 gene is inducible by interleukin-6. J. Mol. Neurosci. 18: 105-109.
58. Cavadini, G. et al. 2007. TNF-alpha suppresses the expression of clock genes by interfering with E-box-mediated transcription. Proc. Natl. Acad. Sci. U.S.A. 104: 12843-12848.
59. Vgontzas, A.N. et al. 2004. Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. J. Clin. Endocrinol. Metab. 89: 2119-2126.
60. Vgontzas, A.N. et al. 2007. Daytime napping after a night of sleep loss decreases sleepiness, improves performance, and causes beneficial changes in cortisol and interleukin-6 secretion. Am. J. Physiol. Endocrinol. Metab. 292: E253-E261.
61. Shearer, W.T. et al. 2001. Soluble TNF-alpha receptor 1 and IL-6 plasma levels in humans subjected to the sleep deprivation model of spaceflight. J. Allergy Clin. Immunol. 107: 165-170.
62. Hogan, D. et al. 2003. Interleukin-6 alters sleep of rats. J. Neuroimmunol. 137: 59-66.
63. Krueger, J.M. & J.A. Majde. 2003. Humoral links between sleep and the immune system: research issues. Ann. N.Y. Acad. Sci. 992: 9-20.
64. Obal, F.J. et al. 1990. Interleukin 1 alpha and an interleukin 1 beta fragment are somnogenic. Am. J. Physiol. 259: R439-R446.
65. Opp, M.R., F.J. Obal & J.M. Krueger. 1991. Interleukin 1 alters rat sleep: temporal and dose-related effects. Am. J. Physiol. 260: R52-R58.
66. Spath-Schwalbe, E. et al. 1998. Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J. Clin. Endocrinol. Metab. 83: 1573-1579.
67. Crofford, L.J. et al. 1997. Circadian relationships between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones: failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. J. Clin. Endocrinol. Metab. 82: 1279-1283.
68. Okun, M.L. et al. 2004. Exploring the cytokine and endocrine involvement in narcolepsy. Brain Behav. Immun. 18: 326-332.
69. Tauman, R., L.M. O'Brien & D. Gozal. 2007. Hypoxemia and obesity modulate plasma C-reactive protein and interleukin-6 levels in sleep-disordered breathing. Sleep Breath 11: 77-84.
70. Teramoto, S., H. Yamamoto & Y. Ouchi. 2003. Increased C-reactive protein and increased plasma interleukin-6 may synergistically affect the progression of coronary atherosclerosis in obstructive sleep apnea syndrome. Circulation 107: E40-E50.
71. Teramoto, S., H. Yamamoto & Y. Ouchi. 2004. Increased plasma interleukin-6 is associated with the pathogenesis of obstructive sleep apnea syndrome. Chest 125: 1964-65; author reply, 1965.
72. Vgontzas, A.N. et al. 2000. Chronic systemic inflammation in overweight and obese adults. JAMA 283: 2235.
73. Mehra, R. et al. 2006. Soluble interleukin 6 receptor: a novel marker of moderate to severe sleep-related breathing disorder. Arch. Intern. Med. 166: 1725-1731.
74. Fragiadaki, K. et al. 2012. Sleep disturbances and interleukin 6 receptor inhibition in rheumatoid arthritis. J. Rheumatol. 39: 60-62.
75. Chauffier, K. et al. 2012. Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis. Rheumatology 51: 60-68.
76. Papanicolaou, D.A. et al. 1996. Exercise stimulates interleukin-6 secretion: inhibition by glucocorticoids and correlation with catecholamines. Am. J. Physiol. 271: E601-E605.
77. Petersen, A.M. & B.K. Pedersen. 2005. The anti-inflammatory effect of exercise. J. Appl. Physiol. 98: 1154-1162.
78. LeMay, L.G., A.J. Vander & M.J. Kluger. 1990. The effects of psychological stress on plasma interleukin-6 activity in rats. Physiol. Behav. 47: 957-961.
79. Zhou, D. et al. 1993. Exposure to physical and psychological stressors elevates plasma interleukin 6: relationship to the activation of hypothalamic-pituitary-adrenal axis. Endocrinology 133: 2523-2530.
80. Steptoe, A., M. Hamer & Y. Chida. 2007. The effects of acute psychological stress on circulating inflammatory factors in humans: a review and meta-analysis. Brain Behav. Immun. 21: 901-912.
81. Brydon, L. et al. 2004. Socioeconomic status and stress-induced increases in interleukin-6. Brain Behav. Immun. 18: 281-290.
82. Hamer, M. & A. Steptoe. 2007. Association between physical fitness, parasympathetic control, and proinflammatory responses to mental stress. Psychosom. Med. 69: 660-666.
83. Pace, T.W. et al. 2009. Effect of compassion meditation on neuroendocrine, innate immune and behavioral responses to psychosocial stress. Psychoneuroendocrinology 34: 87-98.
84. Carroll, J.E. et al. 2011. Negative affective responses to a speech task predict changes in interleukin (IL)-6. Brain Behav. Immun. 25: 232-238.
85. O'Donnell, K. et al. 2008. Self-esteem levels and cardiovascular and inflammatory responses to acute stress. Brain Behav. Immun. 22: 1241-1247.
86. Kiecolt-Glaser, J.K. et al. 2010. Stress, inflammation, and yoga practice. Psychosom. Med. 72: 113-121.
87. Brydon, L. et al. 2009. Synergistic effects of psychological and immune stressors on inflammatory cytokine and sickness responses in humans. Brain Behav. Immun. 23: 217-224.
88. Carpenter, L.L. et al. 2010. Association between plasma IL-6 response to acute stress and early-life adversity in healthy adults. Neuropsychopharmacology 35: 2617-2623.
89. Pace, T.W. et al. 2006. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am. J. Psychiatry 163: 1630-1633.
90. Bierhaus, A. et al. 2003. A mechanism converting psychosocial stress into mononuclear cell activation. Proc. Natl. Acad. Sci. U.S.A. 100: 1920-1925.
91. Wolf, J.M. et al. 2009. Determinants of the NF-kappaB response to acute psychosocial stress in humans. Brain Behav. Immun. 23: 742-749.
92. Sondergaard, S.R. et al. 2000. Changes in plasma concentrations of interleukin-6 and interleukin-1 receptor antagonists in response to adrenaline infusion in humans. Eur. J. Appl. Physiol. 83: 95-98.
93. van Gool, J. et al. 1990. The relation among stress, adrenalin, interleukin 6 and acute phase proteins in the rat. Clin. Immunol. Immunopathol. 57: 200-210.
94. DeRijk, R.H. et al. 1994. Induction of plasma interleukin-6 by circulating adrenaline in the rat. Psychoneuroendocrinology 19: 155-163.
95. von Kanel, R. et al. 2008. Aspirin, but not propranolol, attenuates the acute stress-induced increase in circulating levels of interleukin-6: a randomized, double-blind, placebo-controlled study. Brain Behav. Immun. 22: 150-157.
96. Judd, A.M. 1998. Cytokine expression in the rat adrenal cortex. Horm. Metab. Res. 30: 404-410.
97. Richlin, V.A. et al. 2004. Stress-induced enhancement of NF-kappaB DNA-binding in the peripheral blood leukocyte pool: effects of lymphocyte redistribution. Brain Behav. Immun. 18: 231-237.
98. Hansel, A. et al. 2010. Inflammation as a psychophysiological biomarker in chronic psychosocial stress. Neurosci. Biobehav. Rev. 35: 115-121.
99. Ranjit, N. et al. 2007. Psychosocial factors and inflammation in the multi-ethnic study of atherosclerosis. Arch. Intern. Med. 167: 174-181.
100. Hintikka, J. et al. 2009. Unemployment and ill health: a connection through inflammation? BMC Public Health 9: 410.
101. Lutgendorf, S.K. et al. 1999. Life stress, mood disturbance, and elevated interleukin-6 in healthy older women. J. Gerontol. A Biol. Sci. Med. Sci. 54: M434-M439.
102. von Känel, R. et al. 2006. Effect of Alzheimer caregiving stress and age on frailty markers interleukin-6, C-reactive protein, and D-dimer. J. Gerontol. A Biol. Sci. Med. Sci. 61: 963-969.
103. Clark, M.C. et al. In press. Psychosocial and biological indicators of depression in the care giving population. Biol. Res. Nurs.
104. Kiecolt-Glaser, J.K. et al. 2003. Chronic stress and age-related increases in the proinflammatory cytokine IL-6. Proc. Natl. Acad. Sci. U.S.A. 100: 9090-9095.